On March 15, 2023 Dxcover Limited, a clinical-stage diagnostics company developing spectroscopic liquid biopsy technology for early detection of multiple cancers, reported the upcoming presentation of new data on its liquid biopsy platform at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, to be held in Orlando, Florida from April 14-19 (Press release, Dxcover, MAR 15, 2023, View Source [SID1234628850]). The poster presentation will outline data from a preclinical study evaluating the Dxcover Cancer Liquid Biopsy platform’s capabilities to detect advanced adenomas and early cases of colorectal cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The future of cancer care will depend on reliable and comprehensive methods to detect malignancies earlier, enabling easier treatment and lower rates of recurrence for patients," said Matthew J. Baker, Ph.D., co-founder and Chief Technical Officer of Dxcover. "Dxcover’s proprietary liquid biopsy technology combines novel infrared spectroscopy with artificial intelligence in order to rapidly detect cancers with ideal specificity and sensitivity, and I look forward to sharing the latest data on our platform’s potential to detect cancers early."
Presentation details:
Title: Early colorectal cancer detection with a spectroscopic liquid biopsy
Abstract Number: 6506
Session Title: Early Detection and Molecular Markers of Prevention
Session Date and Time: Wednesday Apr 19, 2023 9:00 AM – 12:30 PM
Location: Orange County Convention Center, Poster Section 28